Geochronology of the middle Eocene Purple Bench locality (Devil’s Graveyard Formation), Trans-Pecos Texas, USA

Purple Bench is a middle Eocene fossil locality in the Devil’s Graveyard Formation of the Trans-Pecos region of West Texas. In addition to yielding a range of taxa characteristic of the Uintan North American Land Mammal Age, the Purple Bench locality is noteworthy in documenting a number of endemic species that are known only from the site. Despite the Uintan character of the mammalian fauna, the absolute age of Purple Bench is a matter of debate. This uncertainty stems from the wide interval of time encompassed by current radiometric dates bracketing the Purple Bench locality and from conflicting magnetostratigraphic correlations in the Devil’s Graveyard Formation. This study constrains the absolute age of the Purple Bench locality through detrital zircon U-Pb geochronological analyses. For these analyses, 147 new detrital zircon U-Pb ages were collected from five tuffaceous sandstones and reworked tuff horizons and analyzed via Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICPMS). These new detrital zircon U-Pb geochronological analyses suggest a maximum depositional age of 43.7 +0.8 / -0.2 Ma for the Purple Bench tuff, a significant marker horizon immediately below the Purple Bench locality. These new maximum depositional age dates presented here provide constraints on the true depositional age of the lower and middle members of the Devil’s Graveyard Formation, bringing clarity to the previously ambiguous age of the fossil-bearing Purple Bench locality. The age constraints presented here also aid the characterization of the temporally and spatially variable Uintan North American Land Mammal Age

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry

Background Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited. Methods Adult patients with AD in the CorEvitas AD registry (2020–2021) who received systemic therapies for 4–12 months prior to enrollment were included based on disease severity: body surface area (BSA) 0%–9% and BSA ≥10%. Demographics, clinical characteristics, and outcomes were assessed using descriptive statistics. Pairwise effect sizes (ES) were used to compare BSA groups. Results The study included 308 patients (BSA 0%–9%: 246 [80%]; BSA ≥10%: 62 [20%]). Despite systemic therapy, both BSA groups reported the use of additional topical therapy and the presence of lesions at difficult locations. Moderate-to-severe AD (vIGA-AD®) was reported by 11% (BSA 0%–9%) and 66% (BSA ≥10%; ES = 0.56) of patients. Mean disease severity scores: total BSA (2% and 22%; ES = 3.59), EASI (1.1 and 11.1; ES = 2.60), and SCORAD (12.1 and 38.0; ES = 1.99). Mean scores for PROs: DLQI (3.7 and 7.5; ES = 0.75), and peak pruritus (2.2 and 4.5; ES = 0.81). Inadequate control of AD was seen in 27% and 53% of patients (ES = 0.23). Conclusions Patients with AD experience a high disease burden despite systemic treatment for 4–12 months. This study provides potential evidence of suboptimal treatment and the need for additional effective treatment options for AD

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry

Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited. Adult patients with AD in the CorEvitas AD registry (2020–2021) who received systemic therapies for 4–12 months prior to enrollment were included based on disease severity: body surface area (BSA) 0%–9% and BSA ≥10%. Demographics, clinical characteristics, and outcomes were assessed using descriptive statistics. Pairwise effect sizes (ES) were used to compare BSA groups. The study included 308 patients (BSA 0%–9%: 246 [80%]; BSA ≥10%: 62 [20%]). Despite systemic therapy, both BSA groups reported the use of additional topical therapy and the presence of lesions at difficult locations. Moderate-to-severe AD (vIGA-AD®) was reported by 11% (BSA 0%–9%) and 66% (BSA ≥10%; ES = 0.56) of patients. Mean disease severity scores: total BSA (2% and 22%; ES = 3.59), EASI (1.1 and 11.1; ES = 2.60), and SCORAD (12.1 and 38.0; ES = 1.99). Mean scores for PROs: DLQI (3.7 and 7.5; ES = 0.75), and peak pruritus (2.2 and 4.5; ES = 0.81). Inadequate control of AD was seen in 27% and 53% of patients (ES = 0.23). Patients with AD experience a high disease burden despite systemic treatment for 4–12 months. This study provides potential evidence of suboptimal treatment and the need for additional effective treatment options for AD. This real-world study assessed clinical characteristics and overall disease burden in adult patients with atopic dermatitis (AD) who were receiving systemic therapy for 4–12 months.Patients reported greater involvement of back and anterior trunk, and lesions at difficult locations. Irrespective of body surface area involvement, patients continued to experience inadequate control of AD, varied disease severity, and impact on quality of life.The study provides potential evidence of suboptimal treatment and the need for effective treatment options for the management of AD. Besides clinical outcomes, treating dermatologists and dermatology practitioners should include patient-reported outcomes in routine clinical care to determine the best treatment options for their patients. This real-world study assessed clinical characteristics and overall disease burden in adult patients with atopic dermatitis (AD) who were receiving systemic therapy for 4–12 months. Patients reported greater involvement of back and anterior trunk, and lesions at difficult locations. Irrespective of body surface area involvement, patients continued to experience inadequate control of AD, varied disease severity, and impact on quality of life. The study provides potential evidence of suboptimal treatment and the need for effective treatment options for the management of AD. Besides clinical outcomes, treating dermatologists and dermatology practitioners should include patient-reported outcomes in routine clinical care to determine the best treatment options for their patients.</p

Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016

Background: Preservatives are often necessary components of commercial products. Large-scale North American studies on preservative allergy are limited. Objective: To evaluate demographics, positive patch test reactions (PPTRs), clinical relevance, and trends for preservatives tested by the North American Contact Dermatitis Group. Methods: We conducted a retrospective cross-sectional analysis of North American Contact Dermatitis Group patch testing results of preservatives from 1994 through 2016. Results: A total of 50,799 patients were tested; 11,338 (22.3%) had a PPTR to at least 1 preservative. The most frequent reactions were to methylisothiazolinone 0.2% aqueous (aq) (12.2%), formaldehyde 2% aq (7.8%), formaldehyde 1% aq (7.8%), quaternium-15 2% petrolatum (pet) (7.7%), and methyldibromo glutaronitrile/phenoxyethanol 2% pet (5.1%). Paraben mix 12% pet (1%), iodopropynyl butylcarbamate 0.1% pet (0.4%), benzyl alcohol 1% pet (0.3%), and phenoxyethanol 1% pet (0.2%) had the lowest PPTRs. Linear regression analysis of preservatives tested showed that only methylchloroisothiazolinone/methylisothiazolinone 0.01% aq (parameter estimate, 0.42; 95% CI, 0.17-0.66; P \u3c.005) had a significant increase in PPTRs over time. Limitations: Collected variables are dependent on clinical judgment. Results may be prone to referral selection bias. Conclusions: This large North American study provides insight on preservative PPTRs and trends from 1994 through 2016